 PRINCETON, N.J., April 12, 2021 GLOBE NEWSWIRE -- Advaxis, Inc. Nasdaq: ADXS the Company, a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced it has entered into definitive agreements with two healthcare-focused, institutional investors for the purchase of i 17,577,400 shares of common stock , ii 7,671,937 pre-funded warrants the Pre-Funded Warrants to purchase 7,671,937 shares of common stock and iii registered common share purchase warrants to purchase 11,244,135 shares of common stock. The Company has also agreed to issue to the investors, in a concurrent private placement, unregistered common share purchase warrants to purchase 14,005,202 shares of the Companys common stock. Each share of common stock and accompanying common share purchase warrant are being sold together at a combined offering price of 0.7921, and each Pre-funded Warrant and accompanying common warrant are being sold together at a combined offering price of 0.7911, pursuant to a registered direct offering, priced at-the-market under Nasdaq rules. The Pre-Funded Warrants are immediately exercisable, at an exercise price of 0.001, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The registered common share purchase warrants will have an exercise price of 0.70 per share, will be immediately exercisable, and will expire five 5 years from the date of issuance. The unregistered common share purchase warrants will have an exercise price of 0.70 per share, will be exercisable fourteen days after the Company increases its authorized share capital, and will expire five 5 years from their initial exercise date collectively, the Offering. 